Loading
A phase 2 trial of Izalontamab brengitecan in chordoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma is a phase 2 interventional study registered as NCT06787664 by Sichuan Baili Pharmaceutical Co., Ltd., with 27 participants enrolled, started 2025-01-16 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1. Conditions listed: Chordoma. No results are recorded here; the registry entry is the source.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).